iRadimed (NASDAQ:IRMD) CEO Roger Susi Sells 5,000 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $93.36, for a total transaction of $466,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,205,000 shares of the company’s stock, valued at $205,858,800. This represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Up 1.1%

Shares of IRMD stock opened at $90.14 on Thursday. iRadimed Corporation has a 52 week low of $50.00 and a 52 week high of $107.90. The stock has a market capitalization of $1.15 billion, a PE ratio of 51.51 and a beta of 1.11. The firm has a 50 day moving average of $98.37 and a two-hundred day moving average of $93.49.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.49 by $0.05. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. The company had revenue of $22.69 million during the quarter, compared to analysts’ expectations of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Analysts expect that iRadimed Corporation will post 1.94 EPS for the current fiscal year.

iRadimed Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were given a $0.20 dividend. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.80 annualized dividend and a yield of 0.9%. This is a boost from iRadimed’s previous quarterly dividend of $0.17. iRadimed’s dividend payout ratio is 45.71%.

Wall Street Analyst Weigh In

Several brokerages have commented on IRMD. Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research report on Monday, December 29th. Lake Street Capital reissued a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Finally, Roth Mkm reaffirmed a “buy” rating and set a $120.00 price objective on shares of iRadimed in a research report on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $120.00.

Institutional Investors Weigh In On iRadimed

Several institutional investors have recently modified their holdings of the company. SG Americas Securities LLC lifted its position in shares of iRadimed by 4.5% during the 1st quarter. SG Americas Securities LLC now owns 73,561 shares of the medical equipment provider’s stock worth $7,081,000 after purchasing an additional 3,170 shares during the last quarter. Hsbc Holdings PLC lifted its position in shares of iRadimed by 19.2% during the 4th quarter. Hsbc Holdings PLC now owns 21,559 shares of the medical equipment provider’s stock worth $2,103,000 after purchasing an additional 3,468 shares during the last quarter. Aristides Capital LLC lifted its position in shares of iRadimed by 5.0% during the 4th quarter. Aristides Capital LLC now owns 27,734 shares of the medical equipment provider’s stock worth $2,698,000 after purchasing an additional 1,309 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock worth $24,893,000 after purchasing an additional 205,783 shares during the last quarter. Finally, Invesco Ltd. lifted its position in shares of iRadimed by 473.9% during the 4th quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock worth $3,418,000 after purchasing an additional 29,010 shares during the last quarter. 92.34% of the stock is owned by hedge funds and other institutional investors.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.